Data from these studies suggest a SMYD3-ASCL2 axis whereby Beta-catenin/TCF4-mediated transcriptional upregulation of SMYD3 leads H3K4me3-mediated ASCL2 activation and ultimately increases self-renewal and tumorigenicity in GC CSCs [53]. This evidence concerns the gene SMYD3 and gastric cancer.